ClinicalTrials.gg
RecruitingNCT06958432Updated Sep 28, 2026

Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)

A Phase 2/3 interventional study of Node-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor and Conventional Radiotherapy plus Chemotherapy in Rectal Cancer, Neoadjuvant Therapies and Immune Checkpoint Therapy, sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Sixth Affiliated Hospital, Sun Yat-sen University · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Sep 28, 2026Start date movedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Rectal Neoplasms by Sixth Affiliated Hospital, Sun Yat-sen University — 27 open to participants now, 27 under way, 3 of them phase 3. Rectal Neoplasms · Sixth Affiliated Hospital, Sun Yat-sen University.

Planned enrollment
3rd of 26
430 · median 100
Started
2025
with 7 others
Phase 2/3
Only one
of the 41
Primary completion
2030-12
later than 25 of 26 live
Registered
33rd of 41
by date

Among the 41 studies in Rectal Neoplasms by Sixth Affiliated Hospital, Sun Yat-sen University, this one is the 3rd largest by planned enrollment of the 26 interventional ones that give a count, is one of 8 that started in 2025, is the only one in phase 2/3, reaches primary completion later than 25 of the 26 other live ones, and was the 33rd registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

27 of the 41 studies in Rectal Neoplasms by Sixth Affiliated Hospital, Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 27 open studies →

Where they have run

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Rectal Neoplasms by Sixth Affiliated Hospital, Sun Yat-sen University, or all of them as a file.
02

Study summary

Most rectal cancers are microsatellite stable (MSS) or mismatch repair-proficient (pMMR) and respond poorly to PD-1 inhibitors. Radiotherapy can enhance tumor antigen release and improve responsiveness to PD-1 blockade in MSS/pMMR rectal cancer. Tumor-draining lymph nodes (TDLNs) are critical sites for anti-tumor immune activation, but radiation-induced damage and fibrosis may impair lymphatic drainage and immune responses. Previous studies have reported a remarkable pathologic complete response (pCR) rate of 77.8% using node-sparing radiotherapy in locally advanced rectal cancer. This study aims to evaluate whether node-sparing short-course radiotherapy followed by sequential chemotherapy and PD-1 blockade can improve complete response rate in the phase II part and event-free survival in phase III part, together with sphincter preservation, treatment tolerance, and prognosis in patients with mid-low pMMR/MSS rectal cancer.

03

Conditions studied

  • Rectal Cancer
  • Neoadjuvant Therapies
  • Immune Checkpoint Therapy
  • Radiotherapy

Browse trials for

04

Who can participate

The criteria were revised on the registry on Sep 28, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Voluntarily signs a written form.

      • Aged between 18 and 75 years at the time of enrollment.
      • (ECOG) performance status of 0 or 1.
      • Expected survival of more than 2 years.
      • confirmed rectal adenocarcinoma.
      • Tumor indicates proficient mismatch repair (pMMR), defined by positive immunohistochemical staining for MLH1, MSH2, MSH6, and PMS2, or molecular testing confirms microsatellite stability (MSS).
      • Clinical stage T3-4N0M0 or TanyN+M0 based on the 8th edition of the AJCC TNM classification, as evaluated by high-resolution MRI ± endoscopic ultrasound/transrectal ultrasonography, with the tumor located in the mid-to-lower rectum below the peritoneal reflection.
      • Prior to enrollment, a qualified surgical attending physician must assess the patient's medical history and confirm eligibility for curative R0 resection.
      • No prior systemic or local anti-tumor treatment for rectal cancer, including radiotherapy, chemotherapy, immunotherapy, biologics, or small-molecule targeted therapy.
      • Adequate organ function, defined as follows:
      • Hematologic (without use of blood components or growth factors within 7 days prior to treatment initiation):
      • (ANC) ≥ 1.5 × 10⁹/L
      • count ≥ 100 × 10⁹/L
      • ≥ 90 g/L
      • Renal:
      • Calculated (CrCl) ≥ 50 mL/min using the Cockcroft-Gault formula:

CrCl (mL/min) = [(140 - age) × weight (kg) × 0.85 (if female)] / (72 × serum creatinine [mg/dL])

  • Urine protein \< 2+ on dipstick or \< 1.0 g per 24-hour collection
  • Hepatic:
  • Total ≤ 1.5 ×
  • and ALT ≤ 2.5 × ULN
  • Serum albumin ≥ 28 g/L
  • Coagulation:
  • and APTT ≤ 1.5 × ULN
  • Cardiac:
  • (LVEF) ≥ 50%
  • Women of must have a negative urine or serum pregnancy test within 3 days prior to initiating study treatment. If the urine test is inconclusive, a serum test must confirm the negative result. Women of childbearing potential who are sexually active with non-sterilized male partners must agree to use highly effective from screening through 120 days after the last dose of study drug. The need for continued contraception beyond this period should be discussed with the investigator.
  • Women of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) and have not undergone menopause (defined as ≥12 months of amenorrhea without alternative medical cause, with FSH levels in the range).
  • Highly effective contraception methods are those with \<1% failure rate per year when used consistently and correctly (e.g., hormonal contraceptives). In addition to barrier methods, hormonal contraception is required. Periodic abstinence and the calendar method are not considered acceptable.
  • Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study requirements.

Exclusion criteria

Exclusion Criteria:

    • Presence of suspected lesions or unresectable locally advanced disease, regardless of clinical stage.

      • History of any other within 5 years prior to enrollment, excluding those considered cured by local therapy (e.g., basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder cancer, or ductal carcinoma in situ of the breast).
      • Lesions initially staged as T1N0 eligible for local excision, or T2N0 suitable for sphincter-preserving surgery after multidisciplinary discussion.
      • Evidence of acute conditions requiring emergency surgery, such as bowel obstruction, perforation, or gastrointestinal bleeding.
      • Synchronous multiple primary rectal cancers.
      • History of pelvic or abdominal radiotherapy.
      • Inability to swallow tablets, malabsorption syndrome, or any condition affecting gastrointestinal absorption.
      • Prior systemic or local anti-tumor therapy for locally advanced rectal cancer, including curative surgery, chemotherapy, radiotherapy, immunotherapy (e.g., , agonists, or cell-based therapies), biologics, or small-molecule targeted therapy.
      • Use of nonspecific immunomodulatory treatments (e.g., interleukins, interferons, thymic peptides, tumor necrosis factor) within 2 weeks prior to study treatment (excluding IL-11 for thrombocytopenia), or use of herbal or traditional Chinese medicines with anti-tumor indications within 1 week prior to treatment.
      • Active disease requiring systemic treatment (e.g., with disease-modifying drugs, , or ) within the past 2 years. Replacement therapies (e.g., thyroid hormone, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic treatments.
      • History of or current interstitial lung disease or non-infectious pneumonitis requiring systemic corticosteroid treatment.
      • History of bleeding disorders or coagulopathy; patients requiring long-term anticoagulation (e.g., atrial fibrillation with CHADS2 score ≥ 2).
      • Uncontrolled comorbidities, including but not limited to: decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe peptic ulcer or gastritis, or psychiatric/social conditions affecting compliance or consent.
      • History of myocarditis, cardiomyopathy, or malignant arrhythmias; unstable angina, heart failure requiring hospitalization, or vascular disease (e.g., aortic aneurysm requiring repair or deep vein thrombosis) within 12 months prior to study treatment; other cardiac conditions impacting safety (e.g., poorly controlled arrhythmia, myocardial infarction, or ischemia).
      • Within 6 months prior to treatment: history of gastroesophageal varices, severe ulcers, non-healed wounds, gastrointestinal perforation, fistulas, bowel obstruction, intra-abdominal abscess, or acute GI bleeding.
      • Arterial thromboembolism, grade ≥3 venous thromboembolism (per v5.0), , stroke, hypertensive crisis, or hypertensive encephalopathy within 6 months prior to study treatment.
      • Acute exacerbation of within 1 month prior to treatment; current hypertension not controlled to \<160/100 mmHg despite antihypertensive medication.
      • Active or prior inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis) or chronic diarrhea.
      • Severe infections within 4 weeks prior to treatment, including complications requiring hospitalization, sepsis, or severe pneumonia; active infections requiring systemic anti-infective therapy within 10 days prior to treatment (excluding antiviral therapy for or ).
      • Major surgery or serious trauma within 30 days prior to treatment; minor local surgery within 3 days (excluding PICC placement).
      • History of immunodeficiency or antibody positivity; long-term systemic corticosteroid or immunosuppressive therapy.
      • Active tuberculosis or suspected TB not ruled out via clinical assessment (e.g., sputum test, chest X-ray); known active syphilis.
      • History of allogeneic organ or hematopoietic stem cell transplantation.
      • Untreated active hepatitis B (HBsAg-positive with HBV DNA > 1,000 copies/mL or 200 IU/mL); active hepatitis C (HCV antibody-positive with detectable HCV RNA).
      • Receipt of a within 30 days prior to treatment or planned live vaccination during the study.
      • Known to any component of the drugs, or history of serious hypersensitivity reactions to monoclonal antibodies.
      • Known history of psychiatric disorders, substance abuse, alcoholism, or drug addiction.
      • Pregnant or breastfeeding women.
      • Any disease, treatment, or abnormal laboratory finding that may interfere with study results, affect full study participation, or is not in the patient's best interest.
      • Systemic or local disease caused by a benign tumor, or tumor-related complications/symptoms that pose high medical risk or survival uncertainty (e.g., leukemoid reaction with WBC > 20 × 10⁹/L, cachexia with >10% weight loss in 3 months prior to screening, or ≤18).
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
430 participants (estimated)

Study arms

  • Experimental
    Node-sparing radiotherapy Group

    Node-sparing short-course radiotherapy followed by sequential chemotherapy and PD-1 inhibitor as total neoadjuvant therapy

    Combination Product: Node-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor

  • Active comparator
    Conventional Group

    Conventional short-course radiotherapy followed by sequential chemotherapy as total neoadjuvant therapy

    Combination Product: Conventional Radiotherapy plus Chemotherapy

Interventions

  • Combination productNode-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor

    Patients will receive node-sparing modified short-course radiotherapy, followed by six cycles of CAPOX chemotherapy combined with a PD-1 inhibitor. After neoadjuvant treatment, patients will either undergo total mesorectal excision (TME) surgery or enter a watch-and-wait strategy based on clinical assessment.

  • Combination productConventional Radiotherapy plus Chemotherapy

    Patients will receive conventional-target short-course radiotherapy, followed by six cycles of CAPOX chemotherapy. After neoadjuvant treatment, patients will either undergo TME surgery or enter a watch-and-wait strategy based on clinical assessment.

06

What researchers measure

Primary outcomes

  1. Complete response (CR) rate

    Phase II: Evaluate whether node-sparing modified short-course radiotherapy followed by sequential chemotherapy and PD-1 inhibitor as total neoadjuvant therapy can improve the complete response (CR) rate in mid/low MSS rectal cancer.

    Time frame: For cCR: from randomization to 2-4 weeks after finishing TNT; no more than 12 weeks after the last dose of systermic therapy. For pCR: from randomization to 2-4 weeks after finishing TME surgery

  2. Event-Free Survival (EFS)

    Phase III: To evaluate whether node-sparing modified short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor can improve Event-Free Survival (EFS) in patients with pMMR/MSS rectal cancer.

    Time frame: From randomization to 3 years after finishing surgery or choosing watch and wait strategy

Secondary outcomes

  1. Sphincter preservation rate

    Time frame: From date of randomization until the date of surgery or the date of watch-and-wait for cCR patients,up to 24-30 weeks

  2. Tumor regression grade (TRG)

    Time frame: From randomization to 2 weeks after finishing surgery

  3. R0 resection rate

    Time frame: From date of randomization until the date of surgery,up to 24-30 weeks

  4. Incidence of treatment-related adverse events (toxicity)

    Time frame: From randomization to 90 days after the last dose of neoadjuvant therapy or 30 days after surgery (whichever is longer)

  5. 3-year distant metastasis rate

    Time frame: From randomization to 3 years after finishing surgery or choosing watch and wait strategy

  6. 3-year local recurrence rate

    Time frame: From randomization to 3 years after finishing surgery or choosing watch and wait strategy

  7. 3-year overall survival (OS) rate

    Time frame: From randomization to 3 years after finishing surgery or choosing watch and wait strategy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Dec 2030, 67 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 6, 2025
StartActual
May 6, 2025
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2031
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 1, 2025→May 6, 2025
Sep 28, 2026
Eligibility
1 inclusion criterion edited, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedTumor biopsy indicates proficient mismatch repair (pMMR), defined by positive immunohistochemical staining for MSH1MLH1, MSH2, MSH6, and PMS2, or molecular testing confirms microsatellite stability (MSS).
  • RemovedAgrees to provide tumor tissue and peripheral blood samples during screening and throughout the study for research purposes.
Sep 28, 2026
Interventions
Changed Conventional Radiotherapy plus Chemotherapy and PD-1 inhibitor→Conventional Radiotherapy plus Chemotherapy
Sep 28, 2026
Primary outcomes
2 time frame changed
What changed in the outcomes
  • Time frameComplete response (CR) rateFrom enrollment to 2 weeks after finishing TNT → For cCR: from randomization to 2-4 weeks after finishing TNT; no more than 12 weeks after the last dose of systermic therapy. For pCR: from randomization to 2-4 weeks after finishing TME surgery
  • Time frameEvent-Free Survival (EFS)From enrollment to 3 years after finishing Surgery → From randomization to 3 years after finishing surgery or choosing watch and wait strategy
Sep 28, 2026
Secondary outcomes
6 time frame changed, 1 removed
What changed in the outcomes
  • RemovedTumor downstaging rateTime frame: From enrollment to 2 weeks after finishing TNT
  • Time frameSphincter preservation rateFrom date of randomization until the date of surgery or the date of watch-and-wait for CR patients,up to 24-30 weeks → From date of randomization until the date of surgery or the date of watch-and-wait for cCR patients,up to 24-30 weeks
  • Time frameTumor regression grade (TRG)From enrollment to 2 weeks after finishing TNT → From randomization to 2 weeks after finishing surgery
  • Time frameIncidence of treatment-related adverse events (toxicity)From enrollment to 2 weeks after finishing TNT → From randomization to 90 days after the last dose of neoadjuvant therapy or 30 days after surgery (whichever is longer)
  • Time frame3-year distant metastasis rateFrom enrollment to 3 years after finishing Surgery → From randomization to 3 years after finishing surgery or choosing watch and wait strategy
  • Time frame3-year local recurrence rateFrom enrollment to 3 years after finishing Surgery → From randomization to 3 years after finishing surgery or choosing watch and wait strategy
  • Time frame3-year overall survival (OS) rateFrom enrollment to 3 years after finishing Surgery → From randomization to 3 years after finishing surgery or choosing watch and wait strategy
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Start date May 1, 2025→May 6, 2025
    Eligibility 1 inclusion criterion edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedTumor biopsy indicates proficient mismatch repair (pMMR), defined by positive immunohistochemical staining for MSH1MLH1, MSH2, MSH6, and PMS2, or molecular testing confirms microsatellite stability (MSS).
    • RemovedAgrees to provide tumor tissue and peripheral blood samples during screening and throughout the study for research purposes.
    Primary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameComplete response (CR) rateFrom enrollment to 2 weeks after finishing TNT → For cCR: from randomization to 2-4 weeks after finishing TNT; no more than 12 weeks after the last dose of systermic therapy. For pCR: from randomization to 2-4 weeks after finishing TME surgery
    • Time frameEvent-Free Survival (EFS)From enrollment to 3 years after finishing Surgery → From randomization to 3 years after finishing surgery or choosing watch and wait strategy
    Secondary outcomes 6 time frame changed, 1 removed
    What changed in the outcomes
    • RemovedTumor downstaging rateTime frame: From enrollment to 2 weeks after finishing TNT
    • Time frameSphincter preservation rateFrom date of randomization until the date of surgery or the date of watch-and-wait for CR patients,up to 24-30 weeks → From date of randomization until the date of surgery or the date of watch-and-wait for cCR patients,up to 24-30 weeks
    • Time frameTumor regression grade (TRG)From enrollment to 2 weeks after finishing TNT → From randomization to 2 weeks after finishing surgery
    • Time frameIncidence of treatment-related adverse events (toxicity)From enrollment to 2 weeks after finishing TNT → From randomization to 90 days after the last dose of neoadjuvant therapy or 30 days after surgery (whichever is longer)
    • Time frame3-year distant metastasis rateFrom enrollment to 3 years after finishing Surgery → From randomization to 3 years after finishing surgery or choosing watch and wait strategy
    • Time frame3-year local recurrence rateFrom enrollment to 3 years after finishing Surgery → From randomization to 3 years after finishing surgery or choosing watch and wait strategy
    • Time frame3-year overall survival (OS) rateFrom enrollment to 3 years after finishing Surgery → From randomization to 3 years after finishing surgery or choosing watch and wait strategy
    Interventions Changed Conventional Radiotherapy plus Chemotherapy and PD-1 inhibitor→Conventional Radiotherapy plus Chemotherapy
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06958432
Responsible party
Yanxin Luo,MD (MD PHD, Sixth Affiliated Hospital, Sun Yat-sen University) — Principal investigator
First posted
May 6, 2025
Start date
May 6, 2025
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Sep 28, 2026

Study contacts

Yanxin Luo, M.D., Ph.D.
Contact
luoyx25@mail.sysu.edu.cn
+86-20-38254221
Yikan Cheng
Contact
15102033641

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion